SUBSCRIBERS
Amgen's new cholesterol drug falls short as sales driver
Biotech giant is anxious for Repatha to make up for slowing sales of older ones
Published Thu, Apr 27, 2017 · 09:50 PM
San Francisco
AMGEN Inc's new cholesterol drug is still struggling to gain traction, missing analysts' estimates at a time when the biotechnology giant is anxious for its newer drugs to make up for slowing sales of its older ones.
Sales of the drug, called Repatha, for the first quarter were US$49 million, the company said on Wednesday.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue